Marinus Pharmaceuticals(MRNS)

Search documents
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit
Prnewswire· 2024-06-13 20:53
NEW YORK, June 13, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds investors a shareholder filed a class action lawsuit on behalf of all persons and entities that purchased securities of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) between March 17, 2021 and May 7, 2024. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by August 5, 2024. The Rosen Law Firm is investigating the Allegations that Marinus Pharmaceuticals, Inc. ...
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Marinus Pharmaceuticals, Inc. - MRNS
GlobeNewswire News Room· 2024-06-13 18:15
The class action concerns whether Marinus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until August 5, 2024, to ask the Court to appoint you as Lead Plaintiff for the class if you are a shareholder who purchased or otherwise acquired Marinus securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com. [Click here for information about joining the class action] NEW YORK, June 13, 2024 (GLOB ...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
GlobeNewswire News Room· 2024-06-12 17:10
LOS ANGELES, June 12, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ: MRNS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, L ...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schal Law Firm
Prnewswire· 2024-06-11 15:15
LOS ANGELES, June 11, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ: MRNS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 17, 2021 and May 7, 2024, inclusive (the "Class ...
MRNS Class Action Alert: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the Class Action Against Marinus Pharmaceuticals, Inc.
GlobeNewswire News Room· 2024-06-11 11:18
SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) securities between March 17, 2021 and May 7, 2024. Marinus describes itself as a "commercial-stage company dedicated to the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the u ...
MARINUS ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Marinus Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
GlobeNewswire News Room· 2024-06-11 01:00
Core Viewpoint - A class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. for allegedly making materially false and misleading statements regarding its business operations and clinical trials [1][6]. Summary by Relevant Sections Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased or acquired Marinus securities between March 17, 2021, and May 7, 2024, inclusive [1]. - Investors have until August 5, 2024, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. Allegations Against Marinus - The lawsuit claims that Marinus defendants understated the risk of failing to meet early-stopping criteria in the RAISE trial [6]. - It is alleged that the defendants did not disclose that failing to meet these criteria could lead to the cessation of the separate Phase 3 RAISE II trial [6]. - As a result, the statements made by the defendants regarding the company's business, operations, and prospects were materially false and misleading [6].
MARINUS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Marinus Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
GlobeNewswire News Room· 2024-06-07 02:00
NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) in the United States District Court for the Eastern District of Pennsylvania on behalf of all persons and entities who purchased or otherwise acquired Marinus securities between March 17, 2021 and May 7, 2024, both dates inclusive (the "Class Period") ...
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Marinus Pharmaceuticals, Inc. (MRNS)
GlobeNewswire News Room· 2024-06-06 18:39
NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania on behalf of all persons or entities who purchased or otherwise acquired Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) securities between March 17, 2021 and May 7, 2024, inclusive (the "Class Period"). The lawsuit seeks to recover damages for the Company's investors under ...
MARINUS PHARMACEUTICALS, INC. (NASDAQ: MRNS) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Marinus Pharmaceuticals, Inc.
GlobeNewswire News Room· 2024-06-06 17:11
Core Viewpoint - Marinus Pharmaceuticals, Inc. is facing a securities class action lawsuit due to alleged failures in disclosing risks related to its clinical trials, leading to significant stock price declines [2][6][7]. Group 1: Legal Action - A securities class action lawsuit has been filed against Marinus Pharmaceuticals for alleged violations of the Securities Exchange Act of 1934, covering the period from March 17, 2021, to May 7, 2024 [6]. - The lawsuit claims that Marinus failed to disclose the risk of not meeting early-stopping criteria in the RAISE trial, which could impact the RAISE II trial [2][6]. Group 2: Stock Performance - Following the announcement of cost-cutting measures and the failure of the RAISE trial to meet early stopping criteria, Marinus' stock price fell over 82%, closing at $1.30 per share on April 15, 2024 [3][13]. - On May 8, 2024, the stock price dropped nearly 9%, closing at $1.43 per share [3]. Group 3: Company Actions - Marinus announced several cost-cutting measures, including halting clinical trial enrollment in the RAISE and RAISE II trials, deferring manufacturing investments, and reducing its workforce by approximately 20% [7]. - The company aims to increase operational efficiency through additional cost reductions across R&D and general and administrative functions [7][10].
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Marinus Pharmaceuticals, Inc. - MRNS
GlobeNewswire News Room· 2024-06-06 15:12
Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Marinus Pharmaceuticals and its officers or directors [1] Company Developments - On April 15, 2024, Marinus announced that its pivotal Phase 3 RAISE trial for intravenous ganaxolone did not meet early stopping criteria and that the company would implement cost reduction activities to extend its cash runway beyond Q4 2024 [3] - Following this announcement, Marinus's stock price dropped by $6.32, or 84.04%, closing at $1.20 per share on April 16, 2024 [3] - On May 8, 2024, Marinus announced the cessation of the Phase 3 Raise II trial in refractory status epilepticus (RSE) and stated that future development in RSE would be assessed after reviewing the RAISE topline data [4] - This announcement led to a further decline in Marinus's stock price by $0.14, or 8.91%, closing at $1.43 per share on May 8, 2024 [4]